CLINICAL TRIAL

Ipilimumab for Multiple Myeloma

1 Prior Treatment
High Risk
Refractory
Relapsed
Stage II
Recruiting · 18+ · All Sexes · Montvale, NJ

This study is evaluating whether a drug which is used to treat melanoma may help treat multiple myeloma.

See full description

About the trial for Multiple Myeloma

Eligible Conditions
Neoplasms, Plasma Cell · Multiple Myeloma · Relapsed Or Refractory Multiple Myeloma

Treatment Groups

This trial involves 2 different treatments. Ipilimumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Ipilimumab
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ipilimumab
FDA approved

Side Effect Profile for 10 MG/KG Ipilimumab + Paclitaxel/ Carbop

10 MG/KG Ipilimumab + Paclitaxel/ Carbop
Show all side effects
38%
Alopecia
36%
Anaemia
32%
Nausea
31%
Decreased appetite
31%
Diarrhoea
30%
Fatigue
25%
Constipation
23%
Neutropenia
20%
Dyspnoea
19%
Vomiting
19%
Pyrexia
18%
Rash
17%
Cough
17%
Asthenia
16%
Arthralgia
16%
Pruritus
16%
Thrombocytopenia
15%
Peripheral sensory neuropathy
14%
Myalgia
13%
Neuropathy peripheral
13%
Insomnia
11%
Hypokalaemia
10%
Platelet count decreased
9%
Leukopenia
9%
Pain in extremity
9%
Weight decreased
8%
Pneumonia
8%
Haemoglobin decreased
8%
Hyponatraemia
8%
Alanine aminotransferase increased
7%
Back pain
7%
Neutrophil count decreased
7%
Bone pain
7%
Dizziness
7%
Aspartate aminotransferase increased
7%
Haemoptysis
7%
Malignant neoplasm progression
6%
Stomatitis
6%
Headache
6%
Hypomagnesaemia
5%
Abdominal pain upper
5%
Chest pain
5%
Dehydration
5%
White blood cell count decreased
5%
Abdominal pain
5%
Oedema peripheral
4%
Musculoskeletal pain
4%
Febrile neutropenia
4%
Paraesthesia
3%
Colitis
2%
Lung infection
2%
Mucosal inflammation
2%
Death
2%
Pulmonary embolism
1%
Chronic obstructive pulmonary disease
1%
Pain
1%
Sudden death
1%
Confusional state
1%
Sepsis
1%
Drug hypersensitivity
1%
Lung abscess
1%
Lung neoplasm malignant
1%
Hyperglycaemia
1%
Metastases to central nervous system
1%
Pneumothorax
1%
Respiratory failure
1%
Acute kidney injury
1%
Urinary tract infection
1%
Lower respiratory tract infection
1%
Syncope
1%
Interstitial lung disease
1%
Hypersensitivity
1%
Atrial fibrillation
1%
Blood creatinine increased
1%
Pneumonitis
1%
General physical health deterioration
1%
Cardio-respiratory arrest
1%
Disease progression
1%
Intestinal perforation
1%
Pulmonary haemorrhage
1%
Infection
1%
Renal failure
1%
Liver function test abnormal
1%
Cerebrovascular accident
1%
Multi-organ failure
0%
Neoplasm progression
0%
Staphylococcal infection
0%
Liver disorder
0%
Suicide attempt
0%
Contusion
0%
Empyema
0%
Hyperthyroidism
0%
Blood thyroid stimulating hormone decreased
0%
Bronchitis chronic
0%
Drug-induced liver injury
0%
Hydrocephalus
0%
Hypotension
0%
Cardiac arrest
0%
Thyroiditis
0%
Cellulitis
0%
Lung cancer metastatic
0%
Metastatic neoplasm
0%
Haemorrhagic anaemia
0%
Brain herniation
0%
Disseminated intravascular coagulation
0%
Intestinal obstruction
0%
Renal function test abnormal
0%
General physical condition abnormal
0%
Gastrointestinal haemorrhage
0%
Phlebitis superficial
0%
Polyneuropathy
0%
Renal impairment
0%
Seizure
0%
Cholangitis
0%
Febrile infection
0%
Tachypnoea
0%
Bronchopneumonia
0%
Cachexia
0%
Tumour lysis syndrome
0%
Spinal pain
0%
Depressed mood
0%
Thrombosis
0%
Pulmonary artery stenosis
0%
Type 2 diabetes mellitus
0%
Cardiogenic shock
0%
Skin ulcer
0%
Orchitis
0%
C-reactive protein increased
0%
Infectious colitis
0%
Atrial flutter
0%
Bone marrow failure
0%
Respiratory distress
0%
Pulmonary tuberculosis
0%
Azotaemia
0%
Hypoxia
0%
Pleural effusion
0%
Tracheobronchitis
0%
Blood glucose increased
0%
Renal colic
0%
Neutropenic sepsis
0%
Hypercalcaemia
0%
Shock haemorrhagic
0%
Tachycardia
0%
Diverticular perforation
0%
Atelectasis
0%
Adrenal insufficiency
0%
Cerebral haemorrhage
0%
Blood pressure decreased
0%
Septic shock
0%
Laryngitis
0%
Acute hepatic failure
0%
Tuberculosis
0%
Device related infection
0%
Pneumonia aspiration
0%
Cardiac failure congestive
0%
Hepatitis
0%
Superior vena cava occlusion
0%
Red blood cell count decreased
0%
Guillain-barre syndrome
0%
Sinus tachycardia
0%
Hyperkalaemia
0%
Dysphagia
0%
Tumour perforation
0%
Ulcerative keratitis
0%
Tubulointerstitial nephritis
0%
Peripheral motor neuropathy
0%
Completed suicide
0%
Hypopituitarism
0%
Brain contusion
0%
Device occlusion
0%
Herpes zoster
0%
Jaundice cholestatic
0%
Lumbar vertebral fracture
0%
Hypoglycaemia
0%
Muscular weakness
0%
Cardiopulmonary failure
0%
Ischaemic stroke
0%
Localised infection
0%
Acute myocardial infarction
0%
Anaemia of malignant disease
0%
Malaise
0%
Supraventricular tachycardia
0%
Erythema
0%
Pharyngitis
0%
Cervical radiculopathy
0%
Orthostatic hypotension
0%
Spinal column injury
0%
Idiopathic pulmonary fibrosis
0%
Small intestine carcinoma
0%
Chills
0%
Cholestasis
0%
Cardiovascular insufficiency
0%
Non-small cell lung cancer
0%
Agranulocytosis
0%
Erythema multiforme
0%
Neoplasm malignant
0%
Tumour compression
0%
Vena cava thrombosis
0%
Vertigo
0%
Bronchitis
0%
Cholecystitis acute
0%
Dysuria
0%
Femur fracture
0%
Rectal haemorrhage
0%
Angina pectoris
0%
Pneumonia bacterial
0%
Swelling face
0%
Hepatic function abnormal
0%
Spinal cord paralysis
0%
Dermatitis
0%
Cardiac failure
0%
Depressed level of consciousness
0%
Hypertension
0%
Hepatocellular injury
0%
Lung squamous cell carcinoma metastatic
0%
Adrenocortical insufficiency acute
0%
Impaired gastric emptying
0%
Pericarditis
0%
Depression
0%
Pancreatitis
0%
Delirium
0%
Nephropathy
0%
Subileus
0%
Colitis ischaemic
0%
Facial paresis
0%
Ileus
0%
Palpitations
0%
Systemic inflammatory response syndrome
0%
Lung infiltration
0%
Acute myeloid leukaemia
0%
Ankle fracture
0%
Overdose
0%
Performance status decreased
0%
Pupils unequal
0%
Diverticulitis
0%
Upper respiratory tract infection
0%
Swelling
0%
Fulminant type 1 diabetes mellitus
0%
Hydrocholecystis
0%
Viraemia
0%
Partial seizures
0%
Embolism
0%
Perivascular dermatitis
0%
Pneumocystis jirovecii pneumonia
0%
Brain injury
0%
Gastroenteritis
0%
Lung disorder
0%
Hypothalamo-pituitary disorder
0%
Myositis
0%
Endocrine disorder
0%
Metastases to liver
0%
Cholangitis acute
0%
Autoimmune colitis
0%
Hepatotoxicity
0%
Apnoea
0%
Post procedural complication
0%
Pericardial effusion
0%
Bile duct stenosis
0%
Asbestosis
0%
Embolism venous
0%
Cardiac tamponade
0%
Cerebral infarction
0%
Colorectal cancer
0%
Device dislocation
0%
Exfoliative rash
0%
Hemiparesis
0%
Encephalopathy
0%
Hiccups
0%
Haematemesis
0%
Peripheral ischaemia
0%
Pancytopenia
0%
Lobar pneumonia
0%
Pathological fracture
0%
Portal vein thrombosis
0%
Pulmonary infarction
0%
Superior vena cava syndrome
0%
Acute pulmonary oedema
0%
Toxicity to various agents
0%
Bronchostenosis
0%
Ventricular fibrillation
0%
Crohn's disease
0%
Arrhythmia
0%
Bronchial disorder
0%
Hip fracture
0%
Ileal perforation
0%
Dermatitis acneiform
0%
Peripheral embolism
0%
Hypophysitis
0%
Neuroendocrine carcinoma
0%
Nasopharyngitis
0%
Pulmonary sepsis
0%
Acute respiratory failure
0%
Radiation pneumonitis
0%
Bronchospasm
0%
Brain oedema
0%
Joint dislocation
0%
Traumatic haemorrhage
0%
Heart injury
0%
Large intestine perforation
0%
Extravasation
0%
Gastroenteritis rotavirus
0%
Leukocytosis
0%
Necrotising fasciitis
0%
Migraine
0%
Pneumothorax spontaneous
0%
Sinusitis
0%
Abdominal abscess
0%
Circulatory collapse
0%
Body temperature increased
0%
Cerebral ischaemia
0%
Endocarditis
0%
Infusion related reaction
0%
Metastases to meninges
0%
Hypersomnia
0%
Fall
0%
Neck pain
0%
Obstructive uropathy
0%
Pneumococcal infection
0%
Spinal compression fracture
0%
Cancer pain
0%
Cholecystitis
0%
Acute respiratory distress syndrome
0%
Eczema
0%
Respiratory tract infection
Alopecia
38%
Anaemia
36%
Nausea
32%
Decreased appetite
31%
Diarrhoea
31%
Fatigue
30%
Constipation
25%
Neutropenia
23%
Dyspnoea
20%
Vomiting
19%
Pyrexia
19%
Rash
18%
Cough
17%
Asthenia
17%
Arthralgia
16%
Pruritus
16%
Thrombocytopenia
16%
Peripheral sensory neuropathy
15%
Myalgia
14%
Neuropathy peripheral
13%
Insomnia
13%
Hypokalaemia
11%
Platelet count decreased
10%
Leukopenia
9%
Pain in extremity
9%
Weight decreased
9%
Pneumonia
8%
Haemoglobin decreased
8%
Hyponatraemia
8%
Alanine aminotransferase increased
8%
Back pain
7%
Neutrophil count decreased
7%
Bone pain
7%
Dizziness
7%
Aspartate aminotransferase increased
7%
Haemoptysis
7%
Malignant neoplasm progression
7%
Stomatitis
6%
Headache
6%
Hypomagnesaemia
6%
Abdominal pain upper
5%
Chest pain
5%
Dehydration
5%
White blood cell count decreased
5%
Abdominal pain
5%
Oedema peripheral
5%
Musculoskeletal pain
4%
Febrile neutropenia
4%
Paraesthesia
4%
Colitis
3%
Lung infection
2%
Mucosal inflammation
2%
Death
2%
Pulmonary embolism
2%
Chronic obstructive pulmonary disease
1%
Pain
1%
Sudden death
1%
Confusional state
1%
Sepsis
1%
Drug hypersensitivity
1%
Lung abscess
1%
Lung neoplasm malignant
1%
Hyperglycaemia
1%
Metastases to central nervous system
1%
Pneumothorax
1%
Respiratory failure
1%
Acute kidney injury
1%
Urinary tract infection
1%
Lower respiratory tract infection
1%
Syncope
1%
Interstitial lung disease
1%
Hypersensitivity
1%
Atrial fibrillation
1%
Blood creatinine increased
1%
Pneumonitis
1%
General physical health deterioration
1%
Cardio-respiratory arrest
1%
Disease progression
1%
Intestinal perforation
1%
Pulmonary haemorrhage
1%
Infection
1%
Renal failure
1%
Liver function test abnormal
1%
Cerebrovascular accident
1%
Multi-organ failure
1%
Neoplasm progression
0%
Staphylococcal infection
0%
Liver disorder
0%
Suicide attempt
0%
Contusion
0%
Empyema
0%
Hyperthyroidism
0%
Blood thyroid stimulating hormone decreased
0%
Bronchitis chronic
0%
Drug-induced liver injury
0%
Hydrocephalus
0%
Hypotension
0%
Cardiac arrest
0%
Thyroiditis
0%
Cellulitis
0%
Lung cancer metastatic
0%
Metastatic neoplasm
0%
Haemorrhagic anaemia
0%
Brain herniation
0%
Disseminated intravascular coagulation
0%
Intestinal obstruction
0%
Renal function test abnormal
0%
General physical condition abnormal
0%
Gastrointestinal haemorrhage
0%
Phlebitis superficial
0%
Polyneuropathy
0%
Renal impairment
0%
Seizure
0%
Cholangitis
0%
Febrile infection
0%
Tachypnoea
0%
Bronchopneumonia
0%
Cachexia
0%
Tumour lysis syndrome
0%
Spinal pain
0%
Depressed mood
0%
Thrombosis
0%
Pulmonary artery stenosis
0%
Type 2 diabetes mellitus
0%
Cardiogenic shock
0%
Skin ulcer
0%
Orchitis
0%
C-reactive protein increased
0%
Infectious colitis
0%
Atrial flutter
0%
Bone marrow failure
0%
Respiratory distress
0%
Pulmonary tuberculosis
0%
Azotaemia
0%
Hypoxia
0%
Pleural effusion
0%
Tracheobronchitis
0%
Blood glucose increased
0%
Renal colic
0%
Neutropenic sepsis
0%
Hypercalcaemia
0%
Shock haemorrhagic
0%
Tachycardia
0%
Diverticular perforation
0%
Atelectasis
0%
Adrenal insufficiency
0%
Cerebral haemorrhage
0%
Blood pressure decreased
0%
Septic shock
0%
Laryngitis
0%
Acute hepatic failure
0%
Tuberculosis
0%
Device related infection
0%
Pneumonia aspiration
0%
Cardiac failure congestive
0%
Hepatitis
0%
Superior vena cava occlusion
0%
Red blood cell count decreased
0%
Guillain-barre syndrome
0%
Sinus tachycardia
0%
Hyperkalaemia
0%
Dysphagia
0%
Tumour perforation
0%
Ulcerative keratitis
0%
Tubulointerstitial nephritis
0%
Peripheral motor neuropathy
0%
Completed suicide
0%
Hypopituitarism
0%
Brain contusion
0%
Device occlusion
0%
Herpes zoster
0%
Jaundice cholestatic
0%
Lumbar vertebral fracture
0%
Hypoglycaemia
0%
Muscular weakness
0%
Cardiopulmonary failure
0%
Ischaemic stroke
0%
Localised infection
0%
Acute myocardial infarction
0%
Anaemia of malignant disease
0%
Malaise
0%
Supraventricular tachycardia
0%
Erythema
0%
Pharyngitis
0%
Cervical radiculopathy
0%
Orthostatic hypotension
0%
Spinal column injury
0%
Idiopathic pulmonary fibrosis
0%
Small intestine carcinoma
0%
Chills
0%
Cholestasis
0%
Cardiovascular insufficiency
0%
Non-small cell lung cancer
0%
Agranulocytosis
0%
Erythema multiforme
0%
Neoplasm malignant
0%
Tumour compression
0%
Vena cava thrombosis
0%
Vertigo
0%
Bronchitis
0%
Cholecystitis acute
0%
Dysuria
0%
Femur fracture
0%
Rectal haemorrhage
0%
Angina pectoris
0%
Pneumonia bacterial
0%
Swelling face
0%
Hepatic function abnormal
0%
Spinal cord paralysis
0%
Dermatitis
0%
Cardiac failure
0%
Depressed level of consciousness
0%
Hypertension
0%
Hepatocellular injury
0%
Lung squamous cell carcinoma metastatic
0%
Adrenocortical insufficiency acute
0%
Impaired gastric emptying
0%
Pericarditis
0%
Depression
0%
Pancreatitis
0%
Delirium
0%
Nephropathy
0%
Subileus
0%
Colitis ischaemic
0%
Facial paresis
0%
Ileus
0%
Palpitations
0%
Systemic inflammatory response syndrome
0%
Lung infiltration
0%
Acute myeloid leukaemia
0%
Ankle fracture
0%
Overdose
0%
Performance status decreased
0%
Pupils unequal
0%
Diverticulitis
0%
Upper respiratory tract infection
0%
Swelling
0%
Fulminant type 1 diabetes mellitus
0%
Hydrocholecystis
0%
Viraemia
0%
Partial seizures
0%
Embolism
0%
Perivascular dermatitis
0%
Pneumocystis jirovecii pneumonia
0%
Brain injury
0%
Gastroenteritis
0%
Lung disorder
0%
Hypothalamo-pituitary disorder
0%
Myositis
0%
Endocrine disorder
0%
Metastases to liver
0%
Cholangitis acute
0%
Autoimmune colitis
0%
Hepatotoxicity
0%
Apnoea
0%
Post procedural complication
0%
Pericardial effusion
0%
Bile duct stenosis
0%
Asbestosis
0%
Embolism venous
0%
Cardiac tamponade
0%
Cerebral infarction
0%
Colorectal cancer
0%
Device dislocation
0%
Exfoliative rash
0%
Hemiparesis
0%
Encephalopathy
0%
Hiccups
0%
Haematemesis
0%
Peripheral ischaemia
0%
Pancytopenia
0%
Lobar pneumonia
0%
Pathological fracture
0%
Portal vein thrombosis
0%
Pulmonary infarction
0%
Superior vena cava syndrome
0%
Acute pulmonary oedema
0%
Toxicity to various agents
0%
Bronchostenosis
0%
Ventricular fibrillation
0%
Crohn's disease
0%
Arrhythmia
0%
Bronchial disorder
0%
Hip fracture
0%
Ileal perforation
0%
Dermatitis acneiform
0%
Peripheral embolism
0%
Hypophysitis
0%
Neuroendocrine carcinoma
0%
Nasopharyngitis
0%
Pulmonary sepsis
0%
Acute respiratory failure
0%
Radiation pneumonitis
0%
Bronchospasm
0%
Brain oedema
0%
Joint dislocation
0%
Traumatic haemorrhage
0%
Heart injury
0%
Large intestine perforation
0%
Extravasation
0%
Gastroenteritis rotavirus
0%
Leukocytosis
0%
Necrotising fasciitis
0%
Migraine
0%
Pneumothorax spontaneous
0%
Sinusitis
0%
Abdominal abscess
0%
Circulatory collapse
0%
Body temperature increased
0%
Cerebral ischaemia
0%
Endocarditis
0%
Infusion related reaction
0%
Metastases to meninges
0%
Hypersomnia
0%
Fall
0%
Neck pain
0%
Obstructive uropathy
0%
Pneumococcal infection
0%
Spinal compression fracture
0%
Cancer pain
0%
Cholecystitis
0%
Acute respiratory distress syndrome
0%
Eczema
0%
Respiratory tract infection
0%
This histogram enumerates side effects from a completed 2017 Phase 3 trial (NCT01285609) in the 10 MG/KG Ipilimumab + Paclitaxel/ Carbop ARM group. Side effects include: Alopecia with 38%, Anaemia with 36%, Nausea with 32%, Decreased appetite with 31%, Diarrhoea with 31%.

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Multiple Myeloma or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Diagnosis of relapsed refractory multiple myeloma defined as more than 2 lines of prior therapy with at least a very good partial remission to most recent salvage therapy.
Patients should have R-ISS stage II or III disease at diagnosis or high risk cytogenetics by IMWG criteria (t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q)) at any time since diagnosis
Willing and able to participate as a research subject and provide informed consent (Note: an LAR may sign the consent form on the partipant's behalf)
Note:. A line of therapy is treatment between diagnosis and progression or between two progressions
Eligible for CD34-selected HSCT according to MSKCC adult BMT guidelines.
Have a 10/10 matched donor Age ≥ 21, < 73 years.
Karnofsky (adult) Performance Status ≥ 70%.
Cardiac: LVEF at rest must be ≥ 50%
< 3x ULN ALT
< 1.5 ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Ipilimumab will improve 2 primary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of 1 year.

Phase I: maximum tolerated dose of Ipilimumab
1 YEAR
A maximum of 12 patients will be accrued and DLTs will be assessed in these patients. If any DLT is observed in more than one of the six patient cohort, a lower dose of ipilimumab will be evaluated in a new six patient cohort.
1 YEAR
Phase II: progression free survival (PFS)
2 YEARS
criteria of the International Myeloma Working Group
2 YEARS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for multiple myeloma?

This review has found that several treatments for multiple myeloma commonly used by current practitioners are underused and have a significant toxicity profile. The use of these treatments is generally restricted. The most commonly used treatments are a thalidomide-based regimen and oral, lenalidomide ondansetron-based induction and, if necessary, autologous stem cell transplants. Many treatments, though still not widely used, exhibit a very good prognosis with a similar safety profile to more commonly used and more current treatments. A number of new treatments are currently under development. Further study of the efficacy of these treatments is necessary to establish the place they will have in modern clinical practice.

Anonymous Patient Answer

What are the signs of multiple myeloma?

Most of the time, patients with multiple myeloma have only subtle symptoms until a bone marrow or CNS tumor is found; when any of these symptoms occur, it can be a warning sign of the disease. A history of bone loss, weakness, and fever should raise suspicion for the disease. Patients with multiple myeloma (M+ disease) can have significant side effects from therapy-related cancers.

Anonymous Patient Answer

Can multiple myeloma be cured?

Treatment with bortezomib plus dexamethasone and high-dose therapy with autotransplantation can be promising, leading to an extremely high proportion of patients achieving a complete responses and long-term progression-free survival.

Anonymous Patient Answer

What is multiple myeloma?

Many patients with multiple myeloma can live full and active lives in the community. Multiple myeloma is a disease that can cause pain, coughing up blood, fatigue, and feeling unwell. The outlook depends on how early the disease is detected and how good the patient's immune systems are to fight the disease.\n

Anonymous Patient Answer

What causes multiple myeloma?

The etiology of multiple myeloma is poorly understood, but it is considered to be the result of abnormal development and function of plasma cells. Recent data are not consistent with the notion that there is an infectious agent, but it may not be possible to exclude a role for a bacterial or fungal cause, based on the clinical and laboratory findings.

Anonymous Patient Answer

How many people get multiple myeloma a year in the United States?

An additional 1130 people will be diagnosed with myeloma a year in the United States during 2019, representing an increment of 13% of the number of cases found this year. The data from 2005 and 2015, along with an increase in the incidence of multiple myeloma between 2002 and 2012, indicates that the incidence continues to rise. The US has the greatest number of people diagnosed with myeloma of any country, and the greatest number of deaths and years of survival. The most prevalent histological subtypes are the light chain and the nonsecretory types. The prognosis of the disease is particularly poor if the patient has the disease for more than 5 years.

Anonymous Patient Answer

Have there been any new discoveries for treating multiple myeloma?

There are advances in treating these patients with multiple myeloma, though they are not common, due to the disease being rare. The key to improving prognosis and quality of life is treatment of complications like bone and spinal cord problems. Patients must be treated for these issues if they are to live a healthier, longer life. [With power (http://www.withpower.com/hcp/hcp/hcp-hcp2.

Anonymous Patient Answer

How serious can multiple myeloma be?

The data supports the findings demonstrating increased cancer-related mortality and decreased time to progression in MM patients with an ISS of 3.5 or more when compared to patients with an ISS between 3.0 and 2.5.

Anonymous Patient Answer

What are the chances of developing multiple myeloma?

In European countries, the chances of developing MM, at any time in life, were estimated at one in five and one in 30 by 60 years for men and women, respectively.

Anonymous Patient Answer

What are the latest developments in ipilimumab for therapeutic use?

Ipilimumab is a drug of the antitumor immunotherapy regimen. In 2010 a strong connection between the expression of ipilimumab receptor CD204 and the survival in patients with multiple myeloma was disclosed. Ipilimumab may represent a unique opportunity to introduce a new therapeutic strategy of treatment of patients with multiple myeloma. The therapeutic effect was observed only for high-dose therapy regimen. For some reasons the mechanism of action is still not clear. However, the clinical trial with high-dose therapy regimen has shown improvement of the therapy efficacy. In a recent study, findings presented in this study showed that the high-dose therapy with targeted therapy may provide good clinical benefits.

Anonymous Patient Answer

How does ipilimumab work?

In general, ipilimumab therapy can be useful for patients with MM whose bone lesion involves > or = 50% of the bone marrow, or whose bone lesions are static or active.

Anonymous Patient Answer

What are the common side effects of ipilimumab?

Ipilimumab has a wide range of common side effects, which can be expected to be present and are often transient. The most severe was fever. The most common side effects were headaches, nausea, and fatigue, although those were uncommon. There was no significant difference between men and women in incidence of any of the common side effects. However, for grade 3 or 4 events, side effects occurred more often in men, and for grade 2 events, there was no significant difference between the incidence of men and women. Side effects usually resolve within 12 months, and only occasional cases of serious side effects have been observed. [Power](http://www.withpower.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Multiple Myeloma by sharing your contact details with the study coordinator.